These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26691813)

  • 1. Pharmacovigilance risk mitigation plans: action in public health to promote the safe use of medication.
    Botelho SF; Reis AM
    Cien Saude Colet; 2015 Dec; 20(12):3897-905. PubMed ID: 26691813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thirteen years of medication alerts issued by the Brazilian Health Regulatory Agency (ANVISA): What is the profile?
    Ferreira VC; Ferreira GC; Baldoni AO
    J Eval Clin Pract; 2020 Jun; 26(3):957-961. PubMed ID: 31290584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin pharmacovigilance in Brazil.
    Junqueira DR; Viana TG; Peixoto ER; Barros FC; Carvalho Md; Perini E
    Rev Assoc Med Bras (1992); 2011; 57(3):322-6. PubMed ID: 21691698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Petitioning the FDA to Improve Pharmaceutical, Device and Public Health Safety by Ordinary Citizens: A Descriptive Analysis.
    Chen BK; Yang YT; Cheng X; Bian J; Bennett CL
    PLoS One; 2016; 11(5):e0155259. PubMed ID: 27171162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing the risks of therapeutic products: proceedings of a workshop.
    Kramer JM
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):619-28. PubMed ID: 15641121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S
    Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Governance and pharmacovigilance in Brazil: a scoping review.
    Moscou K; Kohler JC; MaGahan A
    J Pharm Policy Pract; 2016; 9():3. PubMed ID: 26862438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative analysis of the pharmacovigilance systems of Brazil, Spain, the European Union and the United States based on the information provided by their regulatory agency websites.
    Leal MM; Sanz MM; Ferrando JRC; Martinez-Martinez F
    Daru; 2019 Jun; 27(1):379-387. PubMed ID: 30778915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
    Nicholson S; Peterson J; Yektashenas B
    Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The challenges of nanotechnology for the sanitary vigilance of medication].
    Batista Ade J; Pepe VL
    Cien Saude Colet; 2014 Jul; 19(7):2105-14. PubMed ID: 25014290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic.
    Diak IL; Swank K; McCartan K; Beganovic M; Kidd J; Gada N; Kapoor R; Wolf L; Kangas L; Wyeth J; Salvatore T; Fanari M; LeBoeuf AA; Mishra P; Blum MD; Dal Pan G
    Drug Saf; 2023 Feb; 46(2):145-155. PubMed ID: 36460854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New medicines registered in Brazil: can they be considered as a therapeutic advance?].
    Gava CM; Bermudez JA; Pepe VL; dos Reis AL
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3403-12. PubMed ID: 21120328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution and key elements of the Brazilian pharmacovigilance system: a scoping review beginning with the creation of the Brazilian Health Regulatory Agency.
    Mota DM; Vigo Á; Kuchenbecker RS
    Cad Saude Publica; 2018 Oct; 34(10):e00000218. PubMed ID: 30328994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.